Does Rallies show Form 4 insider transactions for CLRB?

Yes. Rallies tracks CLRB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is CLRB research on Rallies investment advice?

No. Rallies provides research, data, and educational context for CLRB. It does not provide personalized investment advice.

CLRB (Cellectar Biosciences INC NEW) Stock Analysis - Insider Trades

Cellectar Biosciences INC NEW (CLRB) is a publicly traded Healthcare sector company. As of May 21, 2026, CLRB trades at $3.09 with a market cap of $25.09M and a P/E ratio of -0.38. CLRB moved +3.43% today. Year to date, CLRB is -5.37%; over the trailing twelve months it is -59.97%. Its 52-week range spans $2.43 to $67.50. Analyst consensus is strong buy with an average price target of $10.33. Rallies surfaces CLRB's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading CLRB stock inside the company?

Recent CLRB insider activity includes Longcor Jarrod bought 8.68K, CARUSO JAMES V bought 8.68K, NEIS JOHN sold 198, CARUSO JAMES V bought 10.00K, and Longcor Jarrod bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

CLRB Key Metrics

Key financial metrics for CLRB
Metric	Value
Price	$3.09
Market Cap	$25.09M
P/E Ratio	-0.38
EPS	$-8.35
Dividend Yield	0.00%
52-Week High	$67.50
52-Week Low	$2.43
Volume	1.64K
Avg Volume	0
Revenue (TTM)	$0
Net Income	$-21.79M
Gross Margin	0.00%

Recent CLRB Insider Trades

Longcor Jarrod bought 8.68K (~$25.00K) on May 7, 2026.
CARUSO JAMES V bought 8.68K (~$25.00K) on May 7, 2026.
NEIS JOHN sold 198 (~$731.986) on Dec 12, 2025.
CARUSO JAMES V bought 10.00K (~$49.90K) on Jul 2, 2025.
Longcor Jarrod bought 10.00K (~$49.90K) on Jul 2, 2025.

Latest CLRB News

Cellectar Biosciences Secures $140M, Posts 61.8% MRR and 83.6% ORR — May 14, 2026
Cellectar Biosciences YTD Gain 19.7% and 59.3% EPS Estimate Increase, Q1 Call Scheduled — May 11, 2026
Cellectar Biosciences Reports 83.6% ORR, 61.8% MRR and Raises $140M — May 5, 2026
Cellectar Biosciences Reports $21.8M Loss, Eyes EU Filing in Q3 2026 — Mar 4, 2026
Cellectar Biosciences Secures New Patents in Europe, Asia-Pacific, Middle East and Americas Ahead of 3Q26 EMA Filing — Feb 17, 2026

CLRB Analyst Consensus

3 analysts cover CLRB: 0 strong buy, 3 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $10.33.

Common questions about CLRB

Who is trading CLRB stock inside the company?: Recent CLRB insider activity includes Longcor Jarrod bought 8.68K, CARUSO JAMES V bought 8.68K, NEIS JOHN sold 198, CARUSO JAMES V bought 10.00K, and Longcor Jarrod bought 10.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for CLRB?: Yes. Rallies tracks CLRB insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is CLRB research on Rallies investment advice?: No. Rallies provides research, data, and educational context for CLRB. It does not provide personalized investment advice.